Zimmer Biomet Acquires Orthopedic Robotics Company Monogram for $168M

Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty robotic technology.

67d88da8c3e2788ae4185cf9 Web Asset 2
Monogram Technologies

Zimmer Biomet has agreed to acquire all outstanding shares of stock of Monogram Technologies, an orthopedic robotics company, for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million.

Monogram's semi- and fully autonomous robotic technologies are expected to add new capabilities to expand Zimmer Biomet's flagship ROSA Robotics platform and suite of navigation and enabling technologies. Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants in early 2027. Additionally, Monogram is developing a fully autonomous version of the technology with the potential to significantly increase safety, efficiency and outcomes, as well as additional applications beyond TKA. Upon closing of the proposed transaction, Zimmer Biomet expects to have a clear pathway to become the first and only company in orthopedics to offer a fully autonomous surgical robot.

The proposed transaction expands Zimmer Biomet's suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively.

The ROSA platform, which is the cornerstone of Zimmer Biomet's robotics offering, is approaching 2,000 installations worldwide. The company is investing in an R&D pipeline featuring several new product and software applications expected between now and 2027. This includes ROSA Knee with OptimiZe, which has been submitted to the FDA and 510(k) clearance is anticipated later this year, as well as ROSA Posterior Hip and the full commercial launch of ROSA Shoulder.

More